Aptevo highlights preclinical prostate cancer therapy candidate

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/14/2026

1. DPZ
2. NVDA
3. BAC
4. DRS
5. GS
6. AVAV
7. ACI
8. UNH
9. ORCL
10. LQDA

Go back to Aptevo highlights preclinical prostate cancer therapy candidate

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

August 13, 2025 8:05 AM EDT

Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer.

Engineered for precision T-cell activation in prostate cancer; part of Aptevo's growing CRIS-7-derived CD3 portfolio targeting both hematologic and solid tumors

SEATTLE, WA / ACCESS Newswire / August 13, 2025 / Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today reinforced the strategic importance of its preclinical asset APVO442-an... More